Testimony

Senate Hearing – the Women’s Health Protection Act (WHPA)

By M. Isabelle Chaudry | Jun 17, 2021 | Comments Off on Senate Hearing – the Women’s Health Protection Act (WHPA)

Read the NWHN’s written testimony in support of the WHPA.

FDA Meeting – Emergency Use Authorization of the Johnson & Johnson/Janssen Biotech Inc. COVID-19 Vaccine

By Sarah Christopherson | Feb 26, 2021 | Comments Off on FDA Meeting – Emergency Use Authorization of the Johnson & Johnson/Janssen Biotech Inc. COVID-19 Vaccine

Testimony Delivered to the Vaccines and Related Biological Products Advisory Committee

FDA Comments – Possible Emergency Authorization of the Moderna COVID-19 Vaccine

By Cindy Pearson | Dec 17, 2020 | Comments Off on FDA Comments – Possible Emergency Authorization of the Moderna COVID-19 Vaccine

Comments submitted to the Vaccines and Related Biological Products Advisory Committee

FDA Meeting – Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine

By Sarah Christopherson | Dec 10, 2020 | Comments Off on FDA Meeting – Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine

Testimony Delivered to the Vaccines and Related Biological Products Advisory Committee

FDA Meeting – FDA’s Communications About the Safety of Medical Devices

By NWHN Staff | Nov 18, 2020 | Comments Off on FDA Meeting – FDA’s Communications About the Safety of Medical Devices

Oral Presentation Delivered to the Center for Devices and Radiological Health Virtual Public Meeting

FDA Meeting – Development, authorization and licensure of vaccines to prevent COVID-19

By Sarah Christopherson | Oct 22, 2020 | Comments Off on FDA Meeting – Development, authorization and licensure of vaccines to prevent COVID-19

Testimony Delivered to the Vaccines and Related Biological Products Advisory Committee

FDA Comments — Office of Women’s Health Strategic Priorities

By Sarah Christopherson | Sep 8, 2020 | Comments Off on FDA Comments — Office of Women’s Health Strategic Priorities

Public comments urging the FDA’s Office of Women’s Health to ensure that women’s needs are represented across FDA and in the agency’s research, education, and public outreach.

Congressional Hearing — The Disproportionate Impact of COVID-19 on Communities of Color

By M. Isabelle Chaudry | Jun 17, 2020 | Comments Off on Congressional Hearing — The Disproportionate Impact of COVID-19 on Communities of Color

Statement from M. Isabelle Chaudry, Esq., Senior Policy Manager, National Women’s Health Network: House Ways and Means Committee

FDA Meeting – Testing Methods for Asbestos in Talc and Cosmetic Products Containing Talc

By M. Isabelle Chaudry | Feb 4, 2020 | Comments Off on FDA Meeting – Testing Methods for Asbestos in Talc and Cosmetic Products Containing Talc

U.S. Food & Drug Administration Public Meeting on Testing Methods for Asbestos in Talc and Cosmetic Products Containing Talc

Congressional Hearing – Building Consumer Confidence by Empowering FDA to Improve Cosmetic Safety

By M. Isabelle Chaudry | Dec 3, 2019 | Comments Off on Congressional Hearing – Building Consumer Confidence by Empowering FDA to Improve Cosmetic Safety

Testimony Delivered Before the U.S. House of Representatives Committee on Energy and Commerce Subcommittee on Health Hearing “Building Consumer Confidence by Empowering FDA to Improve Cosmetic Safety”